JASPER THERAPEUTICS, INC

Sana Biotechnology's Hypoimmune Cell Therapy Shows Promise in Type 1 Diabetes

4 months ago

• Sana Biotechnology's UP421 demonstrated survival and function of transplanted pancreatic beta cells in a type 1 diabetes patient without immunosuppression. • The first-in-human study showed increased C-peptide levels, indicating insulin production, and sustained signals at the transplant site via MRI. • TD Cowen upgraded Sana Biotechnology to Buy, noting the results meaningfully derisk type 1 diabetes and other applications of the Hypoimmune platform. • The company's stock price surged following the release of the positive data, reflecting investor optimism about the potential of the new treatment.

Jasper Therapeutics' Briquilimab Shows Promise in Chronic Spontaneous Urticaria

4 months ago

• Jasper Therapeutics reported positive preliminary data from its BEACON Phase 1b/2a study of briquilimab in adults with chronic spontaneous urticaria (CSU). • The study demonstrated rapid and durable symptom control, with substantial reductions in UAS7 scores across multiple dosing cohorts. • Complete responses (UAS7 = 0) were observed in 100% of patients in the 240mg single-dose cohort at 8 weeks. • Briquilimab was well-tolerated, supporting the commencement of a CSU registrational program expected in the second half of 2025.

Jasper Therapeutics Advances Stem Cell Conditioning with JSP191 and CD117-Targeted Therapies

7 months ago

• Jasper Therapeutics is focused on advancing safer conditioning agents and stem cell engineering to improve hematopoietic stem cell transplants and gene therapies. • The company's lead compound, JSP191, is a conditioning antibody designed to clear hematopoietic stem cells from the bone marrow, reducing risks associated with current transplant regimens. • Jasper is also developing Briquilimab, targeting CD117, with promising results in preventing allergic conditions like anaphylaxis and allergic asthma in animal models. • Strategic partnerships and recent financial results underscore Jasper's commitment to innovation and expanding the availability of curative therapies.